Virtual Library

Start Your Search

Masafumi Yamaguchi

Author of

  • +

    EP1.01 - Advanced NSCLC (ID 150)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Advanced NSCLC
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.01-105 - Experience in Treating Recurrent Non-Small Lung Cancer Patients After Surgery with Immune-Checkpoint Inhibitor (Now Available) (ID 1148)

      08:00 - 18:00  |  Presenting Author(s): Masafumi Yamaguchi

      • Abstract
      • Slides


      Recent rapid advancements in the development of chemotherapy, including immune checkpoint inhibitors (ICIs), such as program death-1 (PD-1) inhibitor or program death-ligand 1 (PD-L1) inhibitors, in the field of non-small cell lung cancer (NSCLC) have remarkably prolonged patients’ survival.

      Several clinical trials currently underway are assessing the efficacy of ICIs in adjuvant chemotherapy (AC) following complete resection of Stage I-IIIA NSCLC. One of the issues with AC for completely resected NSCLC is the limited proportion of patients who benefit from such treatment, as some patients will experience recurrence despite AC while others will not experience recurrence even without AC.

      Given the emergence of adverse events (AEs), including immune-related AEs at a constant rate, the appropriate timing of treatment with ICI remains unclear whether AC or at the time of recurrence.


      In this single-institutional retrospective study, to clarify the treatment effect of ICIs in terms of the survival or response, we reviewed 21 patients treated with ICIs for recurrent NSCLC who had undergone complete surgical resection between March 2016 and October 2018.


      The median age was 61 years old (range: 47-75 years old). There were 16 men and 5 women. Thirteen patients had adenocarcinoma, 5 had squamous cell carcinoma, and 3 had others. The PD-L1 expression by 22C3 antibody was <1% in 7 patients, 1%-50% in 3 patients, >50% in 5 patients and not done in 6 patients, and the treatment lines of ICIs was first- to second-line in 8 patients and third-line or later in 13 patients. The response was partial response (PR) in 3 patients, stable disease (SD )in 10 patients, progressive disease (PD) in 6 patients and not evaluable in 2 patients. The median overall survival time from the initial administration of ICIs was 22.8 (2.0-80.1) months, while that from surgical resection was 63.7 (9.5-109.7) months.


      The efficacy of administering ICIs after recurrence should be compared with that of AC with ICIs.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.